David A. Siegel Tg Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 123,500 shares of TGTX stock, worth $4.31 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

123,500

Previous 132,400 6.72%

Holding current value

$4.31 Million

Previous $5.22 Million 14.87%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$33.37 - $45.51 $296,993 - $405,039	-8,900 Reduced 6.72%	123,500 $4.44 Million
Q1 2025 May 15, 2025	BUY	$27.67 - $42.99 $3.37 Million - $5.23 Million	121,700 Added 1137.38%	132,400 $5.22 Million
Q4 2024 Feb 14, 2025	SELL	$21.31 - $35.09 $4.58 Million - $7.54 Million	-214,800 Reduced 95.25%	10,700 $322,000
Q3 2024 Nov 14, 2024	BUY	$17.21 - $25.28 $1.02 Million - $1.5 Million	59,400 Added 35.76%	225,500 $5.27 Million
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $2.21 Million - $3.19 Million	166,100 New	166,100 $2.95 Million
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $1.83 Million - $5.79 Million	218,600 Added 29.84%	951,200 $7.95 Million
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $3.24 Million - $7.32 Million	209,000 Added 39.92%	732,600 $18.2 Million
Q1 2023 May 15, 2023	BUY	$10.23 - $19.34 $1.8 Million - $3.41 Million	176,300 Added 50.76%	523,600 $7.87 Million
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $714,426 - $1.69 Million	142,600 Added 69.66%	347,300 $4.11 Million
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $252,721 - $464,520	55,300 Added 37.01%	204,700 $1.21 Million
Q2 2022 Aug 15, 2022	BUY	$3.74 - $10.66 $258,434 - $736,606	69,100 Added 86.05%	149,400 $635,000
Q1 2022 May 16, 2022	BUY	$7.81 - $20.45 $627,143 - $1.64 Million	80,300 New	80,300 $764,000
Q1 2021 May 17, 2021	SELL	$41.61 - $54.3 $303,753 - $396,390	-7,300 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $184,471 - $400,770	7,300 New	7,300 $380,000
Q2 2019 Aug 14, 2019	SELL	$6.27 - $8.65 $283,404 - $390,980	-45,200 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$4.02 - $8.04 $42,611 - $85,223	-10,600 Reduced 19.0%	45,200 $363,000
Q4 2018 Feb 14, 2019	BUY	$3.44 - $5.76 $44,032 - $73,728	12,800 Added 29.77%	55,800 $229,000
Q3 2018 Nov 14, 2018	SELL	$5.15 - $14.0 $46,865 - $127,400	-9,100 Reduced 17.47%	43,000 $241,000
Q2 2018 Aug 14, 2018	BUY	$12.5 - $15.0 $267,500 - $321,000	21,400 Added 69.71%	52,100 $685,000
Q1 2018 May 15, 2018	BUY	$8.7 - $16.8 $267,090 - $515,760	30,700 New	30,700 $436,000
Q4 2017 Feb 14, 2018	SELL	$7.35 - $12.3 $74,970 - $125,460	-10,200 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$10.0 - $12.7 $102,000 - $129,540	10,200	10,200 $121,000

Others Institutions Holding TGTX

# of Institutions

408

Shares Held

92.4M

Call Options Held

2.28M

Put Options Held

1.78M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $5.07B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account